Roche has retained its status as the neurology drugmaker that patient groups hold in the highest esteem, once again completing a clean sweep of PatientView’s corporate reputation rankings. ...
With the help of AI, AstraZeneca’s three-in-one inhaler Breztri has a new furry mascot to help it stand tall over the crowded ...
After Jenny Pearson’s daughter Elise first had a seizure at 16 months old, an MRI came back clean—her brain “looked beautiful ...
Novartis appears to have broken the curse of the BTK inhibitor class. | Novartis appears to have broken the curse of the BTK ...
GSK, Roche and Novartis continued Big Pharma's dealmaking spree with Asian companies. Three midsized Asian biopharmas reached ...
About two years ago, a head-to-head progression-free survival win made Akeso and Summit Therapeutics’ ivonescimab—and the ...
Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry’s top ...
Novartis is taking social media by storm with a multiple sclerosis (MS) campaign that urges patients to #KnowYourMS, a ...
Following a string of customer complaints, a Form 483 and a recall this past spring, a Fresenius manufacturing unit in Utah ...
Since the launch of the Medicare GLP-1 Bridge on July 1, over 500,000 seniors have utilized the program and together saved ...
While a positive advisory committee meeting seemed to up the odds of approval for Replimune’s twice-snubbed melanoma drug in ...
Repatha, also known as evolocumab, was first approved by the FDA in 2015 to help patients lower their LDL, or “bad,” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results